More than 70 mutations on SCN9A have been associated with various clinical phenotypes, among which are pain disorders including gain-of-function disorders PE and paroxysmal extreme pain disorder (PEPD) as well as loss-of-pain disorder congenital insensitivity to pain (CIP) [36, 46, 47]. This evidence concerns the gene SCN9A and paroxysmal extreme pain disorder.